SUBSCRIBE & WIN! Sign up for the Daily CHAT News Today Newsletter for a chance to win a $75 South Country Co-op gift card!

On December 13, 2023, the province announced that access to Trikafta has been expanded, allowing it to be given to children aged two to five. (Photo 102364931 / Health © Sellen | Dreamstime.com)

Alberta expands access to Cystic Fibrosis medication to those aged two to five

Dec 13, 2023 | 3:36 PM

EDMONTON, AB – The Government of Alberta has approved increased access to an important medication.

On December 13, 2023, the province announced that access to Trikafta has been expanded, allowing it to be given to children aged two to five.

Trikafta is used to treat Cystic Fibrosis, a genetic disease in which mucus accumulates in the lungs, digestive tract and other parts of the body, resulting in a persistent cough, shortness of breath, frequent chest infections and weight loss.

Alberta first allowed access to the prescription drug in 2021, allowing for users aged 12 and up to get it. The province then expanded access in 2022, following Health Canada approval for children aged six to 11.

Health Canada approved the expansion to those two to five on October 16, and Alberta announced Wednesday they were following suit.

Adriana LaGrange, Minister of Health said, “We know that innovative, effective medications can enhance the wellbeing of Albertans living with cystic fibrosis. This medication has helped many individuals, and now more children can benefit from the improved health and quality of life provided by this treatment.”

According to Cystic Fibrosis Canada, approximately 40 young Albertans with the F508 gene meet the medical criteria for Trikafta and are eligible for this medication.

Cystic Fibrosis affects over 4,300 people across the country.

READ MORE: Lethbridge News Now.

If you have a news tip, question or concern, please email Lethbridge.newsroom@Pattisonmedia.com.